| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 02/01/2006 | EP1133315B1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases |
| 02/01/2006 | EP0907736B1 Cc-type chemokines |
| 02/01/2006 | EP0264434B2 Detection of a unique chlamydia strain associated with acute respiratory disease |
| 02/01/2006 | CN1729399A Detection or determination of variants of factor XIIA |
| 02/01/2006 | CN1729298A Modified antibodies stably produced in milk and methods of producing same |
| 02/01/2006 | CN1729290A Gene expressed specifically in dopamine-producing neuron precursor cells after termination of division |
| 02/01/2006 | CN1729203A Human monoclonal antibodies against CD20 |
| 02/01/2006 | CN1727359A Compound from catarrh mollase bacterial |
| 02/01/2006 | CN1239701C Humanised antibodies to epidermal growth factor receptor |
| 02/01/2006 | CN1239518C Membrane protein polypeptide having pre-B cell growth-supporting ability and gene thereof |
| 01/31/2006 | US6992177 haptens comprising protease inhibitors such as succinimido-oxycarbonyl-ethylamino-glycyl-glycyl-glutaryl-aminomethyl-(pyr)saquinavir conjugates with hemocyanins, albumin or dextran, used to generate antibodies and immunogens to saquinavir; assays |
| 01/31/2006 | US6992176 Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| 01/31/2006 | US6992174 Reducing the immunogenicity of fusion proteins |
| 01/31/2006 | US6991936 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 01/31/2006 | US6991928 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis |
| 01/31/2006 | US6991920 Peptide for use in human therapeutics and diagnostics |
| 01/31/2006 | US6991911 for detection of 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA) anibody production; drug screening; haptens; immunogens |
| 01/31/2006 | US6991901 Administering an antibody to the polypeptide sec1; angiogenesis inhibitors |
| 01/31/2006 | US6991810 a glycoprotein used as an industrial component such as an antifoulant, or an anti-adhesive, or as a pharmaceutical component such as an anti-inflammatory agent. |
| 01/31/2006 | US6991791 Administering anti- human tumor necrosis factor- alpha (TNF alpha) monoclonal antibody, or a TNF binding fragment for therapy of neurodegenerative disease in a human |
| 01/31/2006 | US6991790 administering sodium chloride-free pharmaceutical formulation comprising antibody that binds CD20, antibody not subjected to prior lyophilization, acetate buffer from pH 4.8- 5.5, surfactant and polyol; treatment of lymphomas, strokes, shock |
| 01/31/2006 | US6991779 Biologically active molecules encapsulated in self-assembling, diketopiperazine microspheres, TECHNOSPHEREs tm ) and methods for making and administering such compositions are described herein. The compositions can be used to immunize individuals |
| 01/31/2006 | CA2203142C A diagnostic assay for alzheimer's disease: assessment of a.beta. abnormalities |
| 01/26/2006 | WO2006009901A2 Novel antigen-binding polypeptides and their uses |
| 01/26/2006 | WO2006009809A2 Vegf inhibitors for the treatment of malignant pleural effusion |
| 01/26/2006 | WO2006009533A1 Anti-glycated cd59 antibodies and uses thereof |
| 01/26/2006 | WO2006009527A1 Tobacco-specific nitrosamine detection assays and reagents |
| 01/26/2006 | WO2006009241A1 Lrp4/CORIN DOPAMINE-PRODUCING NEURON PRECURSOR CELL MARKER |
| 01/26/2006 | WO2006009114A1 Il-18 receptor antagonist and pharmaceutical composition containing the antagonist |
| 01/26/2006 | WO2006008548A2 Binding molecules |
| 01/26/2006 | WO2005115456A9 METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY |
| 01/26/2006 | WO2005105844A3 Preparation of scfv antibody fragments |
| 01/26/2006 | WO2005086595A3 Telomere protein trf2 dna-binding domain mutant protein, telomere dna mutant and utilization of complex structure of trf2 dna-binding domain with double-stranded dna |
| 01/26/2006 | WO2005076843A3 Methods and compositions for treating tumors and metastatic disease |
| 01/26/2006 | WO2005060999A3 Detection of cd20 in therapy of autoimmune diseases |
| 01/26/2006 | WO2005054273A3 Humanized antibodies against vascular endothelial growth factor |
| 01/26/2006 | WO2005035584A8 Fully human antibodies against human 4-1bb (cd137) |
| 01/26/2006 | WO2005012538A3 Accelerated vaccination |
| 01/26/2006 | WO2005005462A3 Blys antagonists and uses thereof |
| 01/26/2006 | WO2004099249A3 Optimized fc variants and methods for their generation |
| 01/26/2006 | WO2004099249A2 Optimized fc variants and methods for their generation |
| 01/26/2006 | WO2004076636A3 A novel human g-protein coupled receptor, hgprbmy23, expressed highly in kidney |
| 01/26/2006 | WO2004072266A3 Antibody affinity engineering by serial epitope-guided complementarity replacement |
| 01/26/2006 | WO2004045532A3 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 01/26/2006 | WO2004045507A3 Anti-angiogenic uses of il-6 antagonists |
| 01/26/2006 | US20060021074 Reducing the risk of human anti-human antibodies through V gene manipulation |
| 01/26/2006 | US20060021069 Antibody production methods related to disruption of peripheral tolerance in B lymphocytes |
| 01/26/2006 | US20060020119 Monoclonal antibodies to gastrin hormone |
| 01/26/2006 | US20060020118 Cytokine specific immunoglobulin for prevention and treatment of diabetes, autoimmune and inflammatory disorders |
| 01/26/2006 | US20060020114 Apo-2DcR |
| 01/26/2006 | US20060020113 Human Six Transmembrane Epithelial Antigen of the Prostate (STEAP) protein; folds in a "serpentine" manner into three extracellular and two intracellular loops; used for diagnosis and treatment of prostate cancer |
| 01/26/2006 | US20060020110 Synthetic peptides that bind to the hepatitis B virus core and E antigens |
| 01/26/2006 | US20060019895 Using soluble frizzled related protein 3 (SFRP-3) and/or Dickkopf-1 (DKK1) expression profiles as evaluative tools in prediciting/diagnosing bone disorders in cancer patients |
| 01/26/2006 | US20060019884 Peptide composition |
| 01/26/2006 | US20060019392 Novel bone mineralization proteins, DNA, vectors, expression systems |
| 01/26/2006 | US20060019344 C-erbB-2 external domain: gp75 |
| 01/26/2006 | US20060019342 Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
| 01/26/2006 | US20060019340 for diagnosing a rheumatoid disease; rheumatoid arthritis and psoriatic arthritis |
| 01/26/2006 | US20060019320 Wnt mediated erbb signalling, compositions and uses related thereto |
| 01/26/2006 | US20060019310 Cell regulatory genes, encoded products, and uses related thereto |
| 01/26/2006 | US20060019294 Tyrosine kinase substrate (Tks) proteins |
| 01/26/2006 | US20060019287 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/26/2006 | US20060019275 Nucleic acids encoding proteins involved in sensory transduction |
| 01/26/2006 | US20060019261 RNA-binding protein |
| 01/26/2006 | US20060019260 Method for tapping the immunological repertoire |
| 01/26/2006 | US20060019252 Genes and polypeptides relating to hepatocellular or colorectal carcinoma |
| 01/26/2006 | US20060019240 Posh nucleic acids, polypeptides and related methods |
| 01/26/2006 | US20060018932 Recombinant protein containing a C-terminal fragment of Plasmodium MSP-1 |
| 01/26/2006 | US20060018920 Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses |
| 01/26/2006 | US20060018919 Peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccines |
| 01/26/2006 | US20060018914 Novel antibody conjugates reactive with human carcinomas |
| 01/26/2006 | US20060018912 Snares for pathogenic or infectious agents and uses related thereto |
| 01/26/2006 | US20060018911 Design of therapeutics and therapeutics |
| 01/26/2006 | US20060018909 Angiopoietin-2 specific binding agents |
| 01/26/2006 | US20060018908 Soluble composition comprising an anti-EGF receptor antibody linked via a carrier moiety to a substituted 3-indoxyl phosphate which is linked to phosphoenolpyruvate. |
| 01/26/2006 | US20060018907 Treating psoriatic arthritis using an antibody that competitively inhibits binding of monoclonal antibody A2 or chimeric monoclonal antibody cA2 to TNF-alpha, and binds to a neutralizing epitope of TNF-alpha with a specified association constant (Ka) determined by Scatchard analysis |
| 01/26/2006 | US20060018906 monoclonal antibody for treating cancer, neovascularization, vascular and arthritic diseases; immunoassay; immunotherapy; inhibition or antagonism of TNF decreases expression of Vascular Endothelial Growth Factor (VEGF) or Vascular Permeability Factor (VPF); decrease angiogenesis |
| 01/26/2006 | US20060018905 Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereof |
| 01/26/2006 | US20060018903 Tumor necrosis factors (TNF); site-directed mutagenesis, genetic deletions; monoclonal antibodies with decreased immunogenicity and lymphocyte epitopes; major histocompatibility complex binding ligands; for treatment of rheumatoid arthritis and Crohn's disease |
| 01/26/2006 | US20060018902 Antibodies to erythropoietin receptor and uses thereof |
| 01/26/2006 | US20060018900 Self antigen vaccines for treating B-cell lymphomas and other cancers |
| 01/26/2006 | US20060018898 Antibody variants |
| 01/26/2006 | US20060018896 Methods for treating conditions associated with lectin-dependent complement activation |
| 01/26/2006 | US20060018895 Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
| 01/26/2006 | US20060018893 Method for determining modulation of P110delta activity |
| 01/26/2006 | US20060018892 nucleic acid molecule comprising nucleotide sequences, that code fro single chain proteins which are serine protease inhibitors, used for prophylaxis of emphysema, cirrhosis, hepatitis, blood disorders, tumors and tumor metastasis |
| 01/26/2006 | US20060018873 inducing in a patient, at least one activity of IL-2 selected from increasing humoral immune responses and increasing cellular immune responses, by administering to said patient a therapeutically effective amount of a peptide sufficient to induce the activity |
| 01/26/2006 | DE10142743B4 Biochips mit Dimorphismus-spezifischen Faktoren aus Candida albicans Biochips with dimorphism-specific factors of Candida albicans |
| 01/26/2006 | CA2612303A1 Anti-glycated cd59 antibodies and uses thereof |
| 01/26/2006 | CA2580336A1 Vh heavy chain only antibodies, and vh heavy chain only dimer compounds and uses thereof |
| 01/26/2006 | CA2574177A1 Lrp4/corin dopaminergic neuron progenitor cell markers |
| 01/26/2006 | CA2574062A1 Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
| 01/26/2006 | CA2570990A1 Expression-enhanced polypeptides |
| 01/26/2006 | CA2570602A1 Agents for regulating the activity of interferon-producing cells |
| 01/26/2006 | CA2568952A1 Novel antigen-binding polypeptides and their uses |
| 01/26/2006 | CA2568534A1 Vegf inhibitors for the treatment of malignant pleural effusion |
| 01/25/2006 | EP1619250A1 WSX receptor and ligands |
| 01/25/2006 | EP1619207A2 HLA-A2.1 binding peptides derived from HCV and their uses |
| 01/25/2006 | EP1618891A1 Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor |
| 01/25/2006 | EP1618890A1 Use of antibodies in a very low dose for the vaccination against cancer |